Preclinical safety evaluation of AAV2-sFLT01 a gene therapy for age-related macular degeneration

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 326-334

  MacLachlan, Timothy K ^a   Lukason, Michael ^a   Collins, Margaret ^b   Munger, Robert ^c   Isenberger, Elisabete ^a   Rogers, Cindy ^a   Malatos, Shana ^a   Dufresne, Elizabeth ^a   Morris, James ^a   Calcedo, Roberto ^d   Veres, Gabor ^e   Scaria, Abraham ^a   Andrews, Laura ^a   Wadsworth, Samuel ^a  

^a GENZYME CORPORATION   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c Animal Ophthalmology Clinic   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e APPLIED GENETIC TECHNOLOGIES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTRORETINOGRAPHY; FEMALE; IMMUNOGENICITY; MALE; NONHUMAN; OPHTHALMOSCOPY; PROTEIN EXPRESSION; RAT; RETINA MACULA AGE RELATED DEGENERATION; SLIT LAMP; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; MACACA FASCICULARIS; MIRIDAE; RATTUS;

EID: 79551622680     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.258     Document Type: Article

References (28)

1. Gottlieb, JL (2002). Age-related macular degeneration. JAMA 288: 2233-2236.
2. Carmeliet, P (2005). Angiogenesis in life, disease and medicine. Nature 438: 932-936.
3. Mitchell, J and Bradley, C (2006). Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes 4: 97.
4. Brown, DM, Kaiser, PK, Michels, M, Soubrane, G, Heier, JS, Kim, RY et al.; ANCHOR Study Group. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
5. Rosenfeld, PJ, Brown, DM, Heier, JS, Boyer, DS, Kaiser, PK, Chung, CY et al.; MARINA Study Group. (2006). Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
6. D'Amico, DJ, Masonson, HN, Patel, M, Adamis, AP, Cunningham, ET Jr, Guyer, DR et al.; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. (2006). Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113: 992-1001.e6.
7. Rasmussen HS, Smith AC, Durham RJ, Rasmussen CS, Bee WH, Wills MC et al. (2003). Safety of intravitreal adenoviral gene therapy containing human pigment epitheliumderived factor transgene in monkeys. Preclinica 77-85.
8. Campochiaro, PA, Nguyen, QD, Shah, SM, Klein, ML, Holz, E, Frank, RN et al. (2006). Adenoviral vector-delivered pigment epithelium-derived factor for neovascular agerelated macular degeneration: results of a phase I clinical trial. Hum Gene Ther 17: 167-176.
9. Van Vliet, KM, Blouin, V, Brument, N, Agbandje-McKenna, M and Snyder, RO (2008). The role of the adeno-associated virus capsid in gene transfer. Methods Mol Biol 437: 51-91.
10. Mueller, C and Flotte, TR (2008). Clinical gene therapy using recombinant adenoassociated virus vectors. Gene Ther 15: 858-863.
11. Kay, MA, Manno, CS, Ragni, MV, Larson, PJ, Couto, LB, McClelland, A et al. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257-261.
12. Marks, WJ Jr, Ostrem, JL, Verhagen, L, Starr, PA, Larson, PS, Bakay, RA et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7: 400-408.
13. Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105.
14. Acland, GM, Aguirre, GD, Bennett, J, Aleman, TS, Cideciyan, AV, Bennicelli, J et al. (2005). Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12: 1072-1082.
15. Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
16. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
17. Cideciyan AV, Hauswirth W, Aleman TS, Kaushal S, Schwartz SB, Boye SL et al. (2009). Human RPE65 gene therapy for leber congenital amaurosis: persistence of early visual improvements and safety at one year. Hum Gene Ther 20: 999-1004.
18. Hauswirth, WW, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979-990.
19. Pechan, P, Rubin, H, Lukason, M, Ardinger, J, DuFresne, E, Hauswirth, WW et al. (2009). Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16: 10-16.
20. Hackett RB and McDonald TO (1996). Assessing ocular irritation. In: Marzuli, FB and Maibach, HI (eds). Dermatotoxicology, 5th edn. Hemisphere Publishing: Washington, DC.
21. Nussenblatt, RB, Palestine, AG, Chan, CC and Roberge, F (1985). Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92: 467-471 .
22. Husain, D, Kim, I, Gauthier, D, Lane, AM, Tsilimbaris, MK, Ezra, E et al. (2005). Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123: 509-516.
23. Suburo, AM and D'Amore, PA (2006). Development of the endothelium. Handb Exp Pharmacol (176 Pt 1): 71-105.
24. Saint-Geniez M, Maharaj ASR, Walshe TE, Tucker BA, Sekiyama E, Kurihara T et al. (2008). Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 3: 1-13.
25. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE and D'Amore PA. (2009). An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 106: 18751-18756.
26. Ueno, S, Pease, ME, Wersinger, DM, Masuda, T, Vinores, SA, Licht, T et al. (2008). Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 217: 13-22.
27. Lai, CM, Shen, WY, Brankov, M, Lai, YK, Barnett, NL, Lee, SY et al. (2005). Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 12: 659-668.
28. Kang, W, Wang, L, Harrell, H, Liu, J, Thomas, DL, Mayfield, TL et al. (2009). An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther 16: 229-239.